bilaterals.org logo
bilaterals.org logo

health


Author discusses ‘monstrous’ prospects for NHS after no-deal Brexit
US president Donald Trump stood next to outgoing-PM Theresa May and insisted the NHS would be “on the table” in any trade deal.
Trade negotiations and the triple trouble for health and the NHS
On Monday, the British parliament will debate whether the NHS should be included in US trade talks. Here’s how to decode the reassuring words we’ll no doubt hear from government.
Tobacco as an ‘offensive interest’ in trade talks? The role of rules of origin
Beyond ISDS, another potential trade policy issue lurks in the background and which has not yet captured the attention of the health policy community: rules of origin in trade agreements.
Tobacco and trade: an unhealthy and harmful marriage
The tobacco industry has a long history of using international trade deals to force their products into new markets.
Free trade can seriously damage your health
These practises open the door to Big Pharma companies and disastrous private health companies.
USMCA (NAFTA 2.0): tightening the constraints on the right to regulate for public health
Rather than enhancing public health protection the USMCA places new, extended, and enforceable obligations on public regulators that increase the power of corporate interests during the development of new regulations.
Aborted for-profit hospital
The Jeju provincial government has revoked the business license of a Chinese-owned for-profit hospital. The Chinese group may file a suit against the Korean government, using the investor-state dispute settlement system.
Will free trade make Africans sick?
African governments must act immediately to address the AfCFTA’s potential negative implications for Africans’ health.
Media release: Philip Morris paying only half of Australia’s costs in ISDS case is outrageous, says AFTINET
It has taken a second FOI case and another two years to reveal that Australian taxpayers were only awarded half of the costs of defending Australia’s tobacco plain packaging laws against tobacco giant Philip Morris in March 2017.
Investment protection proposals under RCEP threaten India’s pharma industry
Free trade agreements like the RCEP will infringe on India’s intellectual property laws. India must stand its ground in the interest of public health.
US ambassador defends farming record on chicken and beef
The UK should accept American meat as part of a post-Brexit trade deal, says US ambassador to the UK .
Korea`s first for-profit hospital in Jeju faces license revocation
The Korea government may face another investor-state dispute case from the Chinese capital if the license is called off.
More than 70 US health, consumer and other groups demand elimination of NAFTA 2.0 terms that would lock in high US medicine prices
In a letter to Congress, the groups demand that the pact’s giveaways to Big Pharma that would keep medicines unaffordable be removed before the pact is sent to Congress.
We can’t afford to let the new NAFTA drive up drug prices
NAFTA 2.0 would effectively tie the US Congress’ hands in the struggle against rising drug prices.
NAFTA 2.0: US-Mexico-Canada Agreement. Chapter 20: pharmaceutical related patent provisions
The Intellectual Property Chapter of the revised NAFTA, rebranded by the Trump Administration USMCA, includes provisions that threaten to undermine critical efforts to­wards affordable health care and medicine.
Indonesia and RCEP: Beware the public health risks
Proposals from Japan and South Korea would require patent law changes in several RCEP countries, including Indonesia.
PHA4: Neoliberal policies and corporate takeover are the cause of the world health crisis
Multinational corporations are suing countries for using generic versions of life saving medicines.
Statement of opposition to the Regional Comprehensive Economic Partnership at the 4th global people’s health assembly, Savar Bangladesh, 15-19 November
We condemn the secretly negotiated Regional Comprehensive Economic Partnership (RCEP) which will erode people’s sovereignty and undermine health equity.
Slovakia does not have to compensate the Union private health insurer
The German Supreme Court dismissed the original arbitration decision against Slovakia concerning the ban on health-insurance companies’ profits.
Drugs costs impact health
Canada’s negotiators extended data protection on biologics without knowing impact on prices.